Search results for:

mycophenolic acid

mycophenolic acid
Brand names: Myfortic
Form Strength
DELAYED RELEASE TABLET, ORAL 180 mg
Display Immunosuppressive Agents Class: 924400
Medication comments:
USP <800> Hazardous Drug Assessment of Risk (AOR)
Per policy, these drugs are exempt from USP <800> handling requirements under normal circumstances.
The following outlines must be followed.
generic (Brand) Route [Packaging: Manufacturer ⇒ Dispense] NIOSH Group
mycophenolic acid (Myfortic) PO [Bulk ⇒ Packager] Non - Antineoplastic
Pharmacy:
Receiving /
Storage /
Preparation

Exposure Risk:
low
 • Handling/preparation PPE Requirements: Single  CX gloves , wash hands after handling
• Receiving from Distributor: Standard
• Pharmacy Storage Area: Carousel
• Packaging/Reconstitution Location: Repackaging area
• Compounding (Non-Sterile/Sterile) Location: n/a
• Omnicell Load: No
Transport • Transport (dose is placed inside a plastic sealable bag): Standard
Nursing:
Storage /
Admin.

Exposure Risk:
low
 • Handling/administration PPE Requirements: Single  CX gloves , wash hands after handling
• Storage of Finished dose in Nursing Area/Procedural Area: Patient Med Drawer
• Signage on Patient Door Required: No
• Manipulation of Dosage Form: Standard
• Special Manipulation for Administration: n/a
Disposal /
Spills		 • Disposal of Drug Waste: Full-  blue bin , trace/packaging- trash
• Disposol of Used PPE: trash bin (inside plastic bag)
• Spill management: n/a
NIOSH Supplemental Information: BBW for first trimester pregnancy loss and increased risk of congenital malformations, BBW for lymphomas and other malignancies; genotoxic in vitro and in vivo
Reason for exemption of USP<800> Containment Requirements: Minimal manipulation for dispensing. Does not require additional manipulation for administering.
Enteral Drug Administration notes.
Generic
(Brand)		 Comments and Considerations Recommendations for Administration with Enteral Nutrition
mycophenolate sodium
(Myfortic)		   Do not use mycophenolate tablets, which cannot be crushed, chewed or cut due to teratogenic risk. Suggest converting
Last updated: Jan. 23, 2023
  • Hazard.Drug Handling(USP 800) USP<800> Hazardous Drug / Assessment of Risk
Lexicomp Online Search

Pharmacy Contact Info:

Main Inpatient Pharmacy: ext 4599, 3503
Fax: 704-878-7283

Director of Pharmacy - Randi Raynor, PharmD: ext 4501
Clinical Coordinator - Laura Rollings, PharmD: ext 4597
Pharmacy Informaticist - Stephen Pringle, PharmD: ext 7645
Pharmacy Technician Supervisor - Amy Wingler, CPhT: ext 7385
Pharmacy Automation Coordinator (Omnicell) - Melissa Fulford, CPhT: ext 3556



This site is intended for the staff of Iredell Memorial Hospital.
While others may view accessible pages, Iredell Memorial Hospital makes no warranty, express or implied,
as to the use of this information outside of Iredell Memorial Hospital.
The content of this policy and procedure document serves as guidance to the delivery of quality patient care.
Care providers are expected to exercise critical thinking and situational awareness skills,
and in specific situations to take such action as is necessary for the delivery of quality patient care.
Copyright © 2024 Rpharmy, LLC ­ All Rights Reserved